Label Image (Lbl500902527)
Progesterone
Product Images NDC 50090-2527
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Progesterone (NDC 50090-2527). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Structural Formula (Pro0g 0003 01)
Table 1 (Pro0g 0003 02)
Table 2 (Pro0g 0003 03)
This appears to be a table showing pharmacokinetic parameters for Estradiol, Estrone, and Equilin levels following the co-administration of Conjugated Estrogens (0.625mg) and Progesterone Capsules (200mg) for twelve days in postmenopausal women. The table lists AUCs and other measurements for the drugs.*
Table 3 (Pro0g 0003 04)
Figure 1 (Pro0g 0003 05)
This is a figure showing the time of ryperpas treatment lasting up to 36 months. The graph has a Y-axis indicating the price, which ranges from 0 to £S8E88, and an X-axis showing time in months, ranging from 0 to 3. There are 4 time intervals labeled on the X-axis: 0, 1, 2, and 3. The graph has 4 data points, where the price is marked for each time interval. The image includes a note mentioning "n = total number of patients left at each time interval." Therefore, it is suggested that the graph shows the duration vs. price of a ryperpas medication over 36 months and the number of patients remaining at each interval.*
Table 4 (Pro0g 0003 06)
Table 5 (Pro0g 0003 07)
Table 6 (Pro0g 0003 08)
This is the result of an adverse reactions report in a 3-year placebo-controlled trial in postmenopausal women taking Progesterone Capsules 200mg with Conjugated Estrogens Placebo 0.625mg. It includes a table with the percentage of patients reporting various adverse reactions such as Headache, Breast Tenderness, Depression, Abdominal Pain, and Breast Carcinoma.*
Table 7 (Pro0g 0003 09)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
